EW - Edwards Lifesciences Corporation

NYSE - NYSE Delayed Price. Currency in USD
168.41
+9.30 (+5.85%)
At close: 4:01PM EST
Stock chart is not supported by your current browser
Previous Close159.11
Open163.00
Bid0.00 x 800
Ask200.00 x 900
Day's Range162.81 - 168.53
52 Week Range121.40 - 175.00
Volume2,305,443
Avg. Volume1,528,798
Market Cap35.206B
Beta (3Y Monthly)0.82
PE Ratio (TTM)50.68
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • Edwards Lifesciences To Host Earnings Conference Call on January 31, 2019
    PR Newswire2 days ago

    Edwards Lifesciences To Host Earnings Conference Call on January 31, 2019

    IRVINE, Calif. , Jan. 17, 2019 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, plans ...

  • PR Newswire4 days ago

    Boston Scientific, Edwards Lifesciences Agree To Global Litigation Settlement

    All Patent Litigation Between the Companies to be Dismissed MARLBOROUGH, Mass. and IRVINE, Calif. , Jan. 15, 2019 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) and Edwards Lifesciences Corporation ...

  • Edwards' SAPIEN 3 Ultra Transcatheter Heart Valve Receives FDA Approval
    PR Newswire22 days ago

    Edwards' SAPIEN 3 Ultra Transcatheter Heart Valve Receives FDA Approval

    IRVINE, Calif., Dec. 28, 2018 /PRNewswire/ -- Edwards Lifesciences Corporation (EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced that the SAPIEN 3 Ultra system has received U.S. Food and Drug Administration (FDA) approval for transcatheter aortic valve replacement in severe, symptomatic aortic stenosis patients who are determined to be at intermediate or greater risk of open-heart surgery. "The advanced SAPIEN 3 Ultra system features enhancements on the valve and a new delivery system to address the needs of both patients and clinicians, building on our best-in-class performance of SAPIEN 3 to further advance and improve patient care," said Larry L. Wood, Edwards' corporate vice president, transcatheter heart valves.

  • Edwards Comments On U.S. Court Decision
    PR Newswirelast month

    Edwards Comments On U.S. Court Decision

    Edwards does not expect to pay the jury award since, earlier this year, the U.S. Patent and Trademark office determined that all asserted claims of the '608 patent were invalid. The jury found that Edwards' foundational U.S. Spenser Patents for transcatheter heart valves are valid, but not infringed by the Lotus devices.

  • GlobeNewswirelast month

    Detailed Research: Economic Perspectives on PayPal, Alphabet, Southern, Interpace Diagnostics Group, Edwards Lifesciences, and Laboratory Corporation of America — What Drives Growth in Today's Competitive Landscape

    NEW YORK, Dec. 07, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • ACCESSWIRElast month

    Today's Research Reports on Trending Tickers: Edwards Lifesciences and Globus Medical

    NEW YORK, NY / ACCESSWIRE / December 7, 2018 / U.S. equities finished modestly lower on Thursday as trade concerns were reignited after the arrest of a Huawei senior executive. The Dow Jones Industrial ...

  • Edwards Lifesciences Outlines Growth Strategy At Annual Investor Conference
    PR Newswirelast month

    Edwards Lifesciences Outlines Growth Strategy At Annual Investor Conference

    IRVINE, Calif. , Dec. 5, 2018 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, will ...

  • Edwards Receives Clearance For HemoSphere Platform With Intelligent Decision-Support Tools
    PR Newswire2 months ago

    Edwards Receives Clearance For HemoSphere Platform With Intelligent Decision-Support Tools

    IRVINE, Calif., Dec. 3, 2018 /PRNewswire/ -- Edwards Lifesciences Corporation (EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, announced that the HemoSphere advanced hemodynamic monitoring platform has received U.S. Food and Drug Administration clearance for the Acumen suite of intelligent decision-support solutions. Acumen HPI (Hypotension Prediction Index) software, which introduces artificial intelligence (AI) to hemodynamic monitoring through a machine learning, data-driven algorithm that indicates the likelihood of a hypotensive, or low blood pressure, event before it occurs. Acumen IQ sensor, a minimally-invasive sensor that enables the Acumen HPI software and automatically updates advanced hemodynamic parameters every 20 seconds.

  • ACCESSWIRE2 months ago

    Today's Research Reports on Trending Tickers: Align Technology and Edwards Lifesciences

    NEW YORK, NY / ACCESSWIRE / November 29, 2018 / Wall Street closed up on Wednesday as dovish comments made by Federal Reserve Chairman Jerome Powell boosted investor optimism. According to the Chairman, Jerome Powell, “Interest rates are still low by historical standards, and they remain just below the broad range of estimates of the level that would be neutral for the economy — that is, neither speeding up nor slowing down growth.” The Dow Jones Industrial Average surged 2.5 percent to close at 25,366.43, while the S&P 500 Index jumped 2.3 percent to close at 2,743.79. “Markets wanted to hear Powell say that there is no preset course of rates, that he is mindful of weaknesses in the global economy, and, most importantly, that tariffs have altered the calculus of the future of the U.S. economy,” Cox said.

  • Edwards' SAPIEN 3 Ultra Transcatheter Heart Valve Receives CE Mark
    PR Newswire2 months ago

    Edwards' SAPIEN 3 Ultra Transcatheter Heart Valve Receives CE Mark

    IRVINE, Calif., Nov. 16, 2018 /PRNewswire/ -- Edwards Lifesciences Corporation (EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced it has received CE Mark for the SAPIEN 3 Ultra system for transcatheter aortic valve replacement in severe, symptomatic aortic stenosis patients. "The SAPIEN 3 Ultra system incorporates enhancements to the valve, as well as a new delivery system, which are designed to further build on the exceptional outcomes of the SAPIEN 3 valve, which has shown extremely low rates of mortality and disabling stroke," said Larry L. Wood, Edwards' corporate vice president, transcatheter heart valves.

  • GlobeNewswire3 months ago

    Report: Developing Opportunities within Merit Medical, Edwards Lifesciences, Norfolk Southern, Chipotle Mexican Grill, SLM, and Dril-Quip — Future Expectations, Projections Moving into 2018

    NEW YORK, Oct. 30, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • ACCESSWIRE3 months ago

    Today's Research Reports on Trending Tickers: Edwards Lifesciences and Acadia Healthcare Company

    Edwards Lifesciences' stock moved 0.68% lower Tuesday, to close the day at $148.30. The stock recorded a trading volume of 2,943,065 shares, which was above its three months average volume of 1,573,616 shares. In the last year, Edwards Lifesciences' shares have traded in a range of 100.20 - 175.00.

  • Edwards Lifesciences Reports Third Quarter Results
    PR Newswire3 months ago

    Edwards Lifesciences Reports Third Quarter Results

    IRVINE, Calif. , Oct. 23, 2018 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today ...

  • Edwards Comments On German Court Decision
    PR Newswire3 months ago

    Edwards Comments On German Court Decision

    IRVINE, Calif., Oct. 23, 2018 /PRNewswire/ -- Edwards Lifesciences Corporation (EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, announced that today the district court in Düsseldorf, Germany, granted Boston Scientific's request for a preliminary injunction on future commercial sales and, therefore, patient treatments using the Edwards SAPIEN 3 Ultra valve in Germany.  The injunction will only become effective if Boston Scientific enforces it and provides a bond of €10 million.

  • Edwards Lifesciences To Host Earnings Conference Call On October 23, 2018
    PR Newswire3 months ago

    Edwards Lifesciences To Host Earnings Conference Call On October 23, 2018

    IRVINE, Calif. , Oct. 9, 2018 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, plans ...

  • Edwards Announces Start Of U.S. Study Of Self-Expanding Transcatheter Heart Valve
    PR Newswire3 months ago

    Edwards Announces Start Of U.S. Study Of Self-Expanding Transcatheter Heart Valve

    IRVINE, Calif., Oct. 8, 2018 /PRNewswire/ -- Edwards Lifesciences Corporation (EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced that it has commenced the U.S. pivotal trial that will study its self-expanding CENTERA transcatheter valve for severe, symptomatic aortic stenosis (AS) patients at intermediate risk of open-heart surgery. "We are pleased to launch this rigorous study, which we believe will build a robust body of evidence to support the use of this feature-rich, self-expanding valve system in the treatment of patients with aortic stenosis," said Larry L. Wood, Edwards' corporate vice president, transcatheter heart valves. Separately, Edwards confirmed it has updated its regulatory filings and is now resuming the commercial introduction of the CENTERA valve in Europe after completing the previously announced minor modification to CENTERA's delivery system.

  • Edwards Lifesciences' Philanthropy Exceeds Every Heartbeat Matters Goal To Impact One Million Underserved People Ahead Of Schedule
    PR Newswire4 months ago

    Edwards Lifesciences' Philanthropy Exceeds Every Heartbeat Matters Goal To Impact One Million Underserved People Ahead Of Schedule

    IRVINE, Calif., Sept. 26, 2018 /PRNewswire/ -- Edwards Lifesciences Corporation (EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, announced at a 60th anniversary educational event that the Every Heartbeat Matters initiative has exceeded the goal to impact the global burden of heart valve disease by supporting the education, screening and treatment of one million underserved people by 2020. With the support of grants from Edwards Lifesciences Foundation and donations of Edwards heart valve technologies, the initiative is now expected to reach a total of 1.5 million underserved people globally by the 2020 target through the cumulative effort of 60 non-profit partners.

  • ACCESSWIRE4 months ago

    Today's Research Reports on Trending Tickers: ABIOMED and Edwards Lifesciences

    The Trump administration imposed a tariff of 10 percent on over $200 billion, which could increase to 25 percent if the two countries are unable to settle, according to L. Thomas Block, Washington policy strategist at Fundstrat Global Advisors. The stock ended the day 7.67% higher at $165.47.

  • Edwards Lifesciences To Present At The 13th Annual Wells Fargo Healthcare Conference
    PR Newswire5 months ago

    Edwards Lifesciences To Present At The 13th Annual Wells Fargo Healthcare Conference

    IRVINE, Calif. , Aug. 30, 2018 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, is ...

  • Edwards Lifesciences To Present at 38th Annual Canaccord Genuity Growth Conference
    PR Newswire6 months ago

    Edwards Lifesciences To Present at 38th Annual Canaccord Genuity Growth Conference

    IRVINE, Calif. , Aug. 2, 2018 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, is ...

  • ACCESSWIRE6 months ago

    Free Stock Performance Review on Boston Scientific and Three Additional Medical Equipment Stocks

    WallStEquities.com follows AxoGen Inc. (NASDAQ: AXGN), Boston Scientific Corp. (NYSE: BSX), Corindus Vascular Robotics Inc. (NYSE American: CVRS), and Edwards Lifesciences Corp. (NYSE: EW). Companies in the Medical Appliances and Equipment space are engaged in the manufacture of medical instruments, such as dental and surgical appliances.

  • Edwards Lifesciences Reports Second Quarter Results
    PR Newswire6 months ago

    Edwards Lifesciences Reports Second Quarter Results

    IRVINE, Calif. , July 26, 2018 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today ...

  • Edwards Comments On CMS Advisory Panel
    PR Newswire6 months ago

    Edwards Comments On CMS Advisory Panel

    "Today's advisory panel meeting provided a review of current and possible future impacts of volume requirements on TAVR centers in the United States.  In the absence of definitive evidence linking high volumes of procedures to high quality outcomes for TAVR patients, we continue to believe the best course of action is to focus on defined quality measures for both new programs and also those continuing to offer this life-saving, less-invasive therapy.

  • Edwards Lifesciences To Host Earnings Conference Call on July 26, 2018
    PR Newswire6 months ago

    Edwards Lifesciences To Host Earnings Conference Call on July 26, 2018

    IRVINE, Calif. , July 12, 2018 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, plans ...

  • Edwards Comments On CMS Initiation Of National Coverage Analysis For TAVR
    PR Newswire7 months ago

    Edwards Comments On CMS Initiation Of National Coverage Analysis For TAVR

    CMS announced that it has opened the NCA to reconsider the National Coverage Determination (NCD) released in 2012 for TAVR. This development was clearly expected and the analysis will examine the extensive body of evidence regarding the clinical, economic and quality of life benefits of TAVR.